Questcor Pharmaceuticals acquires 100% stake in BioVectra - MarketLine Financial Deals

Questcor Pharmaceuticals acquires 100% stake in BioVectra

Questcor Pharmaceuticals acquires 100% stake in BioVectra - MarketLine Financial Deals
Questcor Pharmaceuticals acquires 100% stake in BioVectra
Published Jan 18, 2013
2 pages — Published Jan 18, 2013
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Questcor Pharmaceuticals, Inc., a US-based biopharmaceutical company, has acquired all of the issued and outstanding shares of BioVectra.

  
Source:
Document ID
MA135061_130117
Country
Country
Ticker
QCOR=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Questcor Pharmaceuticals acquires 100% stake in BioVectra" Jan 18, 2013. Alacra Store. Dec 05, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Questcor-Pharmaceuticals-acquires-100-stake-in-BioVectra-2052-92653>
  
APA:
MarketLine Financial Deals. (2013). Questcor Pharmaceuticals acquires 100% stake in BioVectra Jan 18, 2013. New York, NY: Alacra Store. Retrieved Dec 05, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Questcor-Pharmaceuticals-acquires-100-stake-in-BioVectra-2052-92653>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.